Clinical trial NCT04998474: FRAME-001 Personalized Vaccine in NSCLC
Official title: A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Lead sponsor: Frame Pharmaceuticals B.V.
Sponsor class: INDUSTRY
Collaborators: name: Erasmus Medical Center
name: The Netherlands Cancer Institute
name: University Medical Center Groningen
name: Leiden University Medical Center
First posted: 2021-08-10
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Despite encouraging results of programmed cell death protein -1 (PD-1) immune checkpoint inhibitor treatment combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), only the minority of approximately 20% of patients derive durable clinical benefit from such treatment. Patients with stable disease (SD) after four cycles of treatment with PD-1 inhibitor pembrolizumab monotherapy or in combination with chemotherapy (standard of care in advanced NSCLC in the Netherlands) have a low probability of still acquiring a complete response (CR) or durable disease control to such treatment and no other curative standard treatment options are available, emphasizing the need for novel therapeutic approaches. Tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune chckpoint inhibitors. Frames are prevalent in NSCLC patients, with 95% of lung tumors harboring one or more Frames. The entire collection of Frames expressed by a tumor is referred to as the Framome. Vaccination against strongly antigenic neopeptides present in a patient's tumor furnishes a perspective of enhancing the therapeutic effect of the immune checkpoint inhibition in NSCLC with expected limited additional toxicities. The current clinical trial is designed to determine immune response, safety, and clinical response of personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel), and who attained SD after four cycles of such therapy. The personalized FRAME-001 vaccine will be administered during maintenance phase of treatment with pembrolizumab monotherapy.


Eligibility criteria: Inclusion Criteria:

* Pathologically and radiologically confirmed advanced squamous or non-squamous NSCLC with SD after four cycles of treatment with pembrolizumab as monotherapy or in combination with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) and suitable for maintenance treatment with pembrolizumab monotherapy.
* Patient Framome identification and characterization with demonstrated expressed at least three frameshift mutations (Frames) with combined ³100 amino acids (preferably more than 100 amino acids) completed as part of molecular pre-screening.
* Eastern Cooperative Oncology Group (ECOG) £1.
* An expected survival of at least 3 months.
* Presence of tumor lesion(s) suitable for biopsy and radiological assessment as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
* Written informed consent according to International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP).

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* Any active infection that might according to investigator interfere with FRAME-001 vaccination.
* Current use of systemic corticosteroids (or other immunosuppressive agents; \>10mg daily prednisone equivalent). Inhaled, intranasal or topical and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted.
* Live vaccine within 30 days prior to first dose of FRAME-001.

Primary outcomes:
measure: FRAME-001-specific immune responses in peripheral blood after administration of FRAME-001
timeFrame: Week 7, 10, 13, 16, 19 and week 49
Secondary outcomes:
measure: The number of adverse events (AEs) according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
timeFrame: Up to week 22
measure: Evaluation of clinical anti-tumor response and survival after treatment with FRAME-001
timeFrame: Through study completion, an average of 2 years
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Netherlands Cancer Institute - Antoni van Leeuwenhoek
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
city: Rotterdam
country: Netherlands
facility: Erasmus MC
Study officials:
affiliation: Frame Pharmaceuticals B.V.
name: Bob Löwenberg, MD
role: STUDY_CHAIR
affiliation: Erasmus Medical Center
name: J.G.J.V. Aerts, MD
role: PRINCIPAL_INVESTIGATOR
References: